{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.68","pValueComment":"Unadjusted p-value.","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.7","value":"15.8"},{"groupId":"OG001","spread":"25.2","value":"15.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"NSCLC participants only: Pre-treatment levels of PD-L1 percent will be compared according to RECIST response using Wilcoxon rank-sum testing.\n\nPD-L1 percent: The percentage of tumor cells that positively express the PD-L1 protein (programmed cell death ligand 1). Tumors that express high amounts of PD-L1 (\\>50%) may respond well to checkpoint inhibitors (a type of immunotherapy drug).","dispersionType":"Standard Deviation","groups":[{"description":"Participants with confirmed RECIST response of CR or PR.","id":"OG000","title":"Confirmed Responders"},{"description":"Participants without confirmed response of CR or PR.","id":"OG001","title":"Non-responders"}],"paramType":"MEAN","populationDescription":"Participants in the NSCLC cohort with PD-L1 IHC evaluation. This analysis was pre-specified in the protocol to collect, analyze, and report data according to response and not by treatment Arm. Patients were classified into responders and non-responders according to RECIST criteria. PD-L1 percent was compared between these two groups of patients.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Prognostic Effect of PD-L1 Expression","type":"SECONDARY","unitOfMeasure":"Percent expression"}